Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04682639 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis
A Phase 2 study of Eosinophilic Esophagitis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 20
- Study locations
NCT04682639 is a Phase 2 study of Eosinophilic Esophagitis that has completed, run by Pfizer. The registered enrollment target is 108 participants, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT04682639, a Phase 2 study of Eosinophilic Esophagitis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Etrasimod
Study Locations (20)
Alabama
- Clinical Research Center of Alabama, LLC - Birmingham
- GastroHealth - St. Vincent's East - Birmingham
- Digestive Health Specialists - Dothan
- Dothan Eyecare - Dr. Brent McKinley (OCT Procedure Only) - Dothan
- Dothan Surgery Center (Colonoscopy Location) - Dothan
- Pulmonary Associates (PFT Procedure Only, Second Location ) - Dothan
- Flowers Hospital (PFT Procedure Only) - Dothan
- Avant Research Associates, LLC - Huntsville
- Crestwood Medical Center - Huntsville
- Baily Cove Eye Care - Huntsville
- Madison Surgery Center - Madison
- Alabama Eye MD - Vestavia Hills
Arizona
- Arizona Retina Institute/ Phoenix Retina Associates(OCT) - Peoria
- SimonMed Imaging (Imaging) - Peoria
- Arizona Digestive Health - Sun City - Sun City
- Sun City Endoscopy Center (Endoscopy) - Sun City
Arkansas
- Little Rock Eye Clinic - Little Rock
- Four Seasons Allergy and Asthma - Little Rock
- Applied Research Center of Arkansas - Little Rock
- Premier Gastroenterology Endoscopy Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04682639
The ClinicalTrials.gov registry entry for NCT04682639 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (87% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04682639 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04682639 about?
NCT04682639 is a clinical study titled "A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis". The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.
What is the current status of trial NCT04682639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2020-12-15. Estimated completion is 2023-06-30.
What conditions does trial NCT04682639 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT04682639?
The interventions under investigation include: Placebo (DRUG), Etrasimod (DRUG).
Who is sponsoring clinical trial NCT04682639?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04682639 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
RECRUITING · Phase 2
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Zemaira Eosinophilic Esophagitis Pilot Study
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.